Infinity Pharmaceuticals reported 3.49M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.13B 73M
Amgen AMGN:US $ 1.33B 99M
AstraZeneca AZN:LN 3.27B 209M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Cytori Therapeutics CYTX:US $ 2.29M 148K
Eisai 4523:JP 92.31B 18.18B
Eli Lilly And LLY:US $ 1.63B 67.2M
Genocea Biosciences GNCA:US $ 3.6M 473K
Gilead Sciences GILD:US $ 1.36B 274M
GlaxoSmithKline GSK:LN 1.96B 726M
Infinity Pharmaceuticals INFI:US 3.49M 181K
Johnson & Johnson JNJ:US $ 6.23B 288M
Mirati Therapeutics MRTX:US $ 54.23M 277K
Novartis NOVN:VX 3.59B 91M
Pfizer PFE:US $ 3.2B 506M
Seattle Genetics SGEN:US $ 220.26M 46.03M
Tg Therapeutics TGTX:US $ 12.64M 7.97M
Vascular Biogenics VBLT:US 3.16M 237K
YTE INCY:US $ 253.28M 43.69M